Tizona Elects Daniel K. Spiegelman to Its Board of Directors
May 15, 2019 16:00 ET
|
Tizona Therapeutics Inc
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
March 17, 2017 09:07 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™,...
IMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid Year
February 09, 2017 13:39 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and...
Immune Therapeutics Clears Critical Certification Milestone
February 02, 2017 09:40 ET
|
Immune Therapeutics, Inc.
Immune Therapeutics Receives Approval for Lodonal™ from theDominican Republic’s Ministry of Health and Social Assistance ORLANDO, Fla., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics,...
Immune Therapeutics Redeems $656,250 Convertible Note; Company Actively Working to Strengthen Balance Sheet by Year End
November 15, 2016 09:06 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune...
Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
June 15, 2016 14:46 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., June 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and...